About Immunis
Immunis is a company based in Irvine (United States) founded in 2018. Immunis has raised $67.36 million across 4 funding rounds from investors including Remiges Ventures, Continuum Health Ventures and Bold Capital Partners. Immunis offers products and services including IMM01-STEM. Immunis operates in a competitive market with competitors including Flexion Therapeutics, Formation Bio, NuVasive, Ensoma and Eupraxia Pharmaceuticals, among others.
- Headquarter Irvine, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunis, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$67.36 M (USD)
in 4 rounds
-
Latest Funding Round
$11.98 M (USD), Series A
May 28, 2026
-
Investors
Remiges Ventures
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immunis
Immunis offers a comprehensive portfolio of products and services, including IMM01-STEM.
Improves muscle mass and immune function in age-related diseases.
People of Immunis
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Immunis
Immunis has successfully raised a total of $67.36M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $11.98 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immunis
Immunis has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Remiges Ventures, Continuum Health Ventures and Bold Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Remiges Ventures is engaged in biotech venture capital investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Early-stage life sciences and tech focused VC firm investing primarily in the US
|
Locked | Locked | Locked |
Investor details for Immunis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immunis
Investment portfolio details for Immunis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immunis
Detailed financials for Immunis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunis Comparisons
Peer comparison for Immunis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immunis
Immunis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Formation Bio, NuVasive, Ensoma and Eupraxia Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
Smart surgical devices for spinal surgery are developed.
|
|
| Locked | Locked | Locked |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
|
| Locked | Locked | Locked |
Sustained-release drug delivery platform for osteoarthritis therapies is developed.
|
|
| Locked | Locked | Locked |
Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases
|
Detailed competitors of Immunis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunis
Complete news archive for Immunis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunis
Immunis was founded in 2018 and raised its 1st funding round 4 years after it was founded.
Immunis is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Immunis is a funded company, having raised a total of $67.36M across 4 funding rounds to date.
Developer of cell therapies for age-related and disease-related immune deficits. It offers a STEM product line developed from human stem cells that secrete immune modulators for treating muscle atrophy in patients with knee osteoarthritis and muscle performance in seniors with obesity and muscle weakness.
Immunis's top competitors include Flexion Therapeutics, NuVasive and Formation Bio.
Immunis offers IMM01-STEM.
Immunis has 5 investors. Key investors include Remiges Ventures, Continuum Health Ventures, Bold Capital Partners, LifeSpan Vision Ventures, and JLS Fund.